TAVR Demonstrates Clinical Superiority To Surgery In Intermediate Risk Patients

18 April 2016

One year results of PARTNER III Trial with Sapien 3 transcatheter aortic valve presented at ACC 2016

TAVR Demonstrates Clinical Superiority To Surgery In Intermediate Risk Patients New data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve was superior to surgery at one year on a composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation.  In addition, the SAPIEN 3 valve demonstrated clinical superiority at one year on individual assessments of all-cause mortality and of stroke.  The results of the study of 1,078 enrolled patients with severe, symptomatic aortic stenosis were presented as part of the late-breaking clinical trials at the American College of Cardiology's 65th Annual Scientific Session (ACC.16) in Chicago, and simultaneously published online in The Lancet.

"Results from the PARTNER II Trial presented at ACC should establish the SAPIEN 3 valve as the new benchmark for the treatment of intermediate-risk patients with severe, symptomatic aortic stenosis," said Vinod Thourani, M.D., co-director, Structural Heart and Valve Center of the Emory Heart and Vascular Center, chief of cardiothoracic surgery at Emory Hospital Midtown and professor of surgery, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine.  Thourani is the co-principal investigator of the SAPIEN 3 study.  "The size and rigor of this 3,000-patient PARTNER II Trial provide powerful evidence in favor of this therapy for the treatment of patients with aortic stenosis."
« Go back